<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744718</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000878-20</org_study_id>
    <secondary_id>S-20080033</secondary_id>
    <secondary_id>2612-3754</secondary_id>
    <nct_id>NCT00744718</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Carboplatin for Patients With Ovarian Cancer</brief_title>
  <official_title>Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients&#xD;
      with platin resistant ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of first treatment until date of verified progression or death. 12 months of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first treatment until death. Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 9 weeks until progression or death. Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>From date of first documented response until date of progression. Up to 12 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">73</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10 mg/kg every 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 every 5 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically verified epithelial ovarian cancer, primary tubae- or primary&#xD;
             peritoneal cancer (Stage I-IV)&#xD;
&#xD;
          2. Carboplatin resistant ovarian cancer previously treated with a maximum of three&#xD;
             different cytostatic regimens (single substance or in combination).&#xD;
&#xD;
          3. Age ≥ 18 years.&#xD;
&#xD;
          4. Performance status 0-2.&#xD;
&#xD;
          5. Measurable disease according to CA125 GCIG criteria (Gynaecologic Cancer Intergroup)&#xD;
             or RECIST (Response Evaluation Criteria in Solid Tumors) (See appendix I+II)&#xD;
&#xD;
          6. Adequate bonemarrow, liver and kidney function and coagulation parameters (within&#xD;
             seven days of start of treatment).&#xD;
&#xD;
          7. ANC ≥ 1.5*109&#xD;
&#xD;
          8. Thrombocytes ≥ 100*10^9/L&#xD;
&#xD;
          9. Haemoglobin (Hb) ≥ 6 mmol/l&#xD;
&#xD;
         10. Se-bilirubin (BR) ≤ 1.5*ULN (Upper Limit of Normal)&#xD;
&#xD;
         11. Se-transaminase ≤ 2.5*ULN&#xD;
&#xD;
         12. Se-creatinin ≤ 1.5*ULN&#xD;
&#xD;
         13. Urin stix for protein &lt;2+ (If stix shows protein ≥2+ urin must be measured 24 hours&#xD;
             where the protein content must be under 1 g.)&#xD;
&#xD;
         14. INR ≤1.5&#xD;
&#xD;
         15. APTT ≤ 1.5*ULN&#xD;
&#xD;
         16. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received other types of experimental treatment or participated in a&#xD;
             clinical study less than 28 days prior to this study.&#xD;
&#xD;
          2. Pregnant or breastfeeding women. A negative pregnancy test is mandatory for fertile&#xD;
             women.&#xD;
&#xD;
          3. Fertile women, who do not wish to use safe contraception (e.g., birth control pills,&#xD;
             coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and&#xD;
             transdermal deposit band-aid).&#xD;
&#xD;
          4. Untreated bowel obstruction or massive gastrointestinal tumors verified by CT scan.&#xD;
&#xD;
          5. Other present or previous malignant disease apart from curatively treated non-melanoma&#xD;
             skin cancer or other types of cancer with minimal risk of relapse.&#xD;
&#xD;
          6. CNS-metastases.&#xD;
&#xD;
          7. Underlying medical disease not adequately treated (diabetes, cardiovascular disease).&#xD;
&#xD;
          8. Uncontrolled hypertension (persistent BP &gt; 150/100 despite antihypertensive&#xD;
             treatment).&#xD;
&#xD;
          9. Surgery incl. open biopsy less than 4 weeks before expected first dose of Bevacizumab.&#xD;
&#xD;
         10. Patients with non-healing wounds or fractures.&#xD;
&#xD;
         11. Previous cerebrovascular attack (TVA), transient ischaemic attack (TIA) or&#xD;
             subarachnoidal bleeding (SAH) within last six months.&#xD;
&#xD;
         12. Thromboembolic or haemorrhagic disease in the anamnesis.&#xD;
&#xD;
         13. Clinically significant cardiovascular disease including Myocardial infarction or&#xD;
             unstable angina less than 6 months prior to treatment&#xD;
&#xD;
               -  New York heart Association NYHA class ≥ 2&#xD;
&#xD;
               -  Poorly controlled cardial arrythmia despite medical treatment&#xD;
&#xD;
               -  Peripheral vascular disease, grade 3 or above.&#xD;
&#xD;
         14. Present or previous chronical use of Aspirin (less than 10 days before start of&#xD;
             treatment) Aspirin &gt; 325 mg daily.&#xD;
&#xD;
         15. Present or recent use of full dose oral or parenteral anticoagulant or thrombolytic&#xD;
             medicine.&#xD;
&#xD;
         16. Preexisting neuropathy, sensoric or motoric ≥ grade 2.&#xD;
&#xD;
         17. Decreased hearing.&#xD;
&#xD;
         18. Bleeding tumor.&#xD;
&#xD;
         19. Hypersensitivity to the active substance or one or more of the other substances&#xD;
             contained in the protocol drugs.&#xD;
&#xD;
         20. Hypersensitivity to products from ovarian cells (CHO) from Chinese hamster or other&#xD;
             recombinant or humanized antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

